
Adaptimmune Therapeutics (ADAP)
Order type
Buy in
Order amount
Est. shares
0 shares
Buy Adaptimmune Therapeutics (ADAP) Stock
Start investing in Adaptimmune Therapeutics (ADAP)
About Adaptimmune Therapeutics (ADAP)
Market cap | $62.48M |
Today's volume | 532 |
Revenue (TTM) | $180.2M |
Avg. daily volume | 1.78M |
EBITDA (TTM) | -$45.23M |
Open | $0.25 |
Price / earnings ratio | -0.88x |
Today's range | $0.24 - $0.26 |
Debt / equity | — |
52 week range | $0.2 - $1.48 |
5 year debt / equity | 135.8x |
Beta (LTM) | 1.37x |
Interest coverage | -19.06x |
Dividend & yield | $0.00 (0.00%) |
Current ratio | 2.02x |
Ex-dividend date | — |
Next earnings | Aug 11, 2025 |
Dividend payable date | — |
Adaptimmune Therapeutics Stock Rating
Adaptimmune Therapeutics Stock News
View all



Frequently Asked Questions (FAQ)
How to buy ADAP stock on Public
- 1
Sign up for a brokerage account on Public
It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.
- 2
Add funds to your Public account
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.
- 3
Choose how much you'd like to invest in ADAP stock
Navigate to the Explore page. Then, type ADAP into the search bar. When you see ADAP stock appear in the results, tap it to open up the purchase screen.
- 4
Manage your investments in one place
You can find your newly purchased ADAP stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.
Adaptimmune Therapeutics Stock Earnings
The value each ADAP share was expected to gain vs. the value that each ADAP share actually gained.
Adaptimmune Therapeutics (ADAP) reported Q1 2025 earnings per share (EPS) of -$0.03, beating estimates of -$0.17 by 82.35%. In the same quarter last year, Adaptimmune Therapeutics's earnings per share (EPS) was -$0.18. Adaptimmune Therapeutics is expected to release next earnings on 08/11/2025, with an earnings per share (EPS) estimate of -$0.14.